#USA #oncology #Frisco, Texas #MiBA #AllyGPO

AllyGPO and MiBA: A Strategic Partnership to Revolutionize Community Oncology

On January 8, 2026, AllyGPO, a forward-looking oncology drug group purchasing organization, and MiBA, a company renowned for its AI-driven oncology analytics, announced an innovative partnership aimed at transforming access to data in community oncology practices. This collaboration not only seeks to bridge knowledge gaps in oncology care but also strives to foster enhanced patient outcomes through data-driven approaches.

In a landscape where independent oncology practices often confront challenges regarding access to vital clinical information, this partnership introduces a new framework. Leveraging MiBA's sophisticated data insights alongside AllyGPO's practice intelligence center, known as AllyIQ®, the two organizations are set to revolutionize the way oncology practices operate. The integration of real-world clinical data with contracting intelligence will empower practices to make informed, data-driven decisions that positively impact patient care.

Bridging Data Gaps in Oncology

The primary objective of this strategic alliance is to address long-standing information voids in community oncology, a sector that increasingly relies on efficient and evidence-based decision-making. MiBA’s validated data engine, combined with AllyGPO’s extensive contracting expertise, enables the realization of GPO agreements that yield significant value for both community oncology and pharmaceutical partners. As a result, a pipeline of new partnerships and therapies is slated for activation in 2026, further underscoring the commitment to advancing oncology practices.

Jason Baroff, Managing Partner of MiBA, expressed, "MiBA was founded to transform oncology through insights that truly serve the community. Partnering with AllyGPO amplifies that mission, delivering insights that enhance patient care while encouraging practices to rethink what's possible."

Mark Moch, another Managing Partner at MiBA, emphasized the transformative potential of this partnership: "This collaboration enables community oncology to move beyond outdated business models. By merging our high-accuracy AI analytics with AllyGPO's comprehensive platform, we’re empowering practices to excel in a new era of data-driven healthcare."

A New Era for Independent Practices

For AllyGPO, this partnership represents a significant step towards aligning with community practices that are dedicated to improving healthcare delivery. Brian Ansay, the CEO of AllyGPO, highlighted the importance of transparency, innovation, and value in fostering relationships with independent practices. "By collaborating with MiBA, we are enhancing our ability to support an expanding network of independent community oncology practices, all geared towards providing the highest quality of patient care."

Aaron Denning, Chief Commercial Officer of AllyGPO, lauded the synergy created between the two organizations. He stated, “The collaboration between AllyGPO's contracting strengths, AllyIQ's analytics, and MiBA’s progressive clinical tools is nothing short of game-changing for community oncology. Together, we are equipping practices with timely insights that directly improve patient outcomes and empower them to spearhead the next wave of community oncology solutions.”

Looking Forward: A Unified Vision

As AllyGPO and MiBA embark on this journey together, the expectations for enhanced patient care and efficient practices are high. This partnership embodies a collective vision for the future of oncology, reflecting a concerted effort to harness data in ways that had previously been unimagined. Inspired by mutual goals, both organizations invite the larger oncology community to join them in this pivotal transformation.

In conclusion, the partnership between AllyGPO and MiBA signifies an exciting leap towards comprehensive, data-informed oncology practices. By capitalizing on advanced analytics and innovative insights, they aim not just to improve operational efficiency but to redefine what is achievable within community oncology, ensuring that patient welfare remains at the heart of their missions.